| scholarly article | Q13442814 |
| P356 | DOI | 10.1359/JBMR.090731 |
| P698 | PubMed publication ID | 19594305 |
| P50 | author | Thomas A Einhorn | Q37368119 |
| P2093 | author name string | Torsten Johansson | |
| Per Aspenberg | |||
| Bruce H Mitlak | |||
| Harry K Genant | |||
| Christopher P Recknor | |||
| Antonio J Nino | |||
| Anke Fierlinger | |||
| Kelly Krohn | |||
| Gail P Dalsky | |||
| Kyoungah See | |||
| Mark C Lakshmanan | |||
| Pedro A García-Hernández | |||
| P433 | issue | 2 | |
| P921 | main subject | bone fracture | Q68833 |
| P304 | page(s) | 404-414 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures | |
| P478 | volume | 25 |
| Q37109477 | 2011 AOA Symposium: Tissue Engineering and Tissue Regeneration: AOA critical issues |
| Q35723052 | A fracture does not adversely affect bone mineral density responses after teriparatide treatment |
| Q34239864 | A literature review and case series of accelerating fracture healing in postmenopausal osteoporotic working women |
| Q37720665 | A new contralateral atypical femoral fracture despite sequential therapy with teriparatide and strontium ranelate. |
| Q36687130 | A review of periprosthetic femoral fractures associated with total hip arthroplasty |
| Q35610534 | A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. |
| Q38241347 | A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia |
| Q34031056 | A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo |
| Q38045470 | Advances and future directions for management of trauma patients with musculoskeletal injuries |
| Q96955307 | Alcohol-induced Wnt signaling inhibition during bone fracture healing is normalized by intermittent parathyroid hormone treatment |
| Q36800210 | Algodystrophy (CRPS) in minor orthopedic surgery |
| Q35590754 | An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH. |
| Q55411806 | Anabolic Strategies to Augment Bone Fracture Healing. |
| Q35078764 | Anabolic agents and bone quality |
| Q52600423 | Anabolic agents: what is beyond osteoporosis? |
| Q36645593 | Annotation: parathyroid hormone and fracture healing |
| Q30410872 | Antioxidative fullerol promotes osteogenesis of human adipose-derived stem cells |
| Q92152417 | Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide |
| Q35425860 | Are biologic treatments a potential approach to wear- and corrosion-related problems? |
| Q50211910 | Atraumatic segmental atypical femur fracture secondary to bisphosphonate use: A case report |
| Q33681406 | Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study |
| Q90406811 | Atypical femoral fractures and current management |
| Q38257133 | Atypical femur fractures: a review |
| Q30411793 | BMP-non-responsive Sca1+ CD73+ CD44+ mouse bone marrow derived osteoprogenitor cells respond to combination of VEGF and BMP-6 to display enhanced osteoblastic differentiation and ectopic bone formation |
| Q36907632 | Biologic adjuvants for fracture healing |
| Q84444255 | Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men |
| Q33826620 | Bisphosphonate's and Intermittent Parathyroid Hormone's Effect on Human Spinal Fusion: A Systematic Review of the Literature |
| Q37733851 | Bisphosphonates and atypical subtrochanteric fractures of the femur. |
| Q90449747 | Bone biology in the elderly: clinical importance for fracture treatment |
| Q55285137 | Bone grafts and biomaterials substitutes for bone defect repair: A review. |
| Q28076668 | Bone healing in 2016 |
| Q35593289 | Bone healing: little secrets |
| Q36746873 | CORR Insights(®): Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial |
| Q64089381 | Can Three Months of Teriparatide Be One of Treatment Options for Osteoporotic Vertebral Compression Fracture Patients? |
| Q33965633 | Can an anti-fracture agent heal fractures? |
| Q39016219 | Cartilage to bone transformation during fracture healing is coordinated by the invading vasculature and induction of the core pluripotency genes. |
| Q35570031 | Cell sources for bone tissue engineering: insights from basic science. |
| Q37886780 | Choosing a treatment for patients at the time a fracture is presented |
| Q36352226 | Combination of calcium sulfate and simvastatin-controlled release microspheres enhances bone repair in critical-sized rat calvarial bone defects |
| Q33763613 | Combined effect of teriparatide and low-intensity pulsed ultrasound for nonunion: a case report |
| Q33693519 | Complications and outcomes of minimally invasive percutaneous plating for proximal humeral fractures |
| Q58765386 | Continuous infusion of PTH delayed fracture healing in mice |
| Q36852779 | Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts |
| Q36317186 | Current Role and Application of Teriparatide in Fracture Healing of Osteoporotic Patients: A Systematic Review |
| Q57174713 | Current advances for bone regeneration based on tissue engineering strategies |
| Q30613107 | Cutting edge: Parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. |
| Q35659476 | Delayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction |
| Q92599680 | Different effects of Wnt/β-catenin activation and parathyroid hormone on diaphyseal and metaphyseal in the early phase of femur bone healing of mice |
| Q34545924 | Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy. |
| Q87328669 | Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw |
| Q34575759 | Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy. |
| Q36746818 | Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial |
| Q91783603 | Dysfunctional stem and progenitor cells impair fracture healing with age |
| Q37581504 | Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing. |
| Q90450541 | Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review |
| Q26771709 | Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review |
| Q55280231 | Effect of high-frequency loading and parathyroid hormone administration on peri-implant bone healing and osseointegration. |
| Q38595303 | Effect of osteoporosis medications on fracture healing |
| Q36340343 | Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study. |
| Q41440677 | Effect of teriparatide on unstable pertrochanteric fractures |
| Q36229660 | Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis |
| Q51832370 | Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. |
| Q92030293 | Effects of Intermittent Administration of Parathyroid Hormone and Parathyroid Hormone-Related Protein on Fracture Healing: A Narrative Review of Animal and Human Studies |
| Q43782888 | Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks |
| Q89998398 | Effects of Weekly Teriparatide Administration for Vertebral Stability and Bony Union in Patients with Acute Osteoporotic Vertebral Fractures |
| Q37893520 | Effects of anti-osteoporosis medications on fracture healing |
| Q36082140 | Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures |
| Q35916945 | Endogenous tissue engineering: PTH therapy for skeletal repair. |
| Q47104721 | Enhanced bone healing and decreased pain in sacral insufficiency fractures after teriparatide treatment: retrospective clinical-based observational study |
| Q89966476 | Evaluation and Management of Osteoporosis and Sarcopenia in Patients with Distal Radius Fractures |
| Q38981442 | Fracture healing physiology and the quest for therapies for delayed healing and nonunion |
| Q48822821 | Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group |
| Q26851958 | Fracture healing: mechanisms and interventions |
| Q38696886 | Fracture repair: general aspects and influence of osteoporosis and anti-osteoporosis treatment |
| Q85322220 | Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide |
| Q42650829 | High dose teriparatide (rPTH1-34) therapy increases callus volume and enhances radiographic healing at 8-weeks in a massive canine femoral allograft model. |
| Q36236833 | Identification and Characterization of a Synthetic Osteogenic Peptide. |
| Q50226090 | Injectable PLGA/Hydroxyapatite/Chitosan Microcapsules Produced by Supercritical Emulsion Extraction Technology: An In Vitro Study on Teriparatide/Gentamicin Controlled Release. |
| Q49884730 | Integrative Approach to Facilitate Fracture Healing: Topical Chinese Herbal Paste with Oral Strontium Ranelate. |
| Q37243627 | Inter-trabecular bone formation: a specific mechanism for healing of cancellous bone |
| Q36072673 | Intermittent Parathyroid Hormone Enhances Cancellous Osseointegration of a Novel Murine Tibial Implant |
| Q64078435 | Intermittent Parathyroid Hormone Injection Can Decrease Femoral Head Collapse in the Vascular Deprivation of Rat Femoral Head Model |
| Q31051550 | Locally administrated perindopril improves healing in an ovariectomized rat tibial osteotomy model |
| Q37620384 | Long-term Bisphosphonate Therapy-induced Periprosthetic Femoral Stress Fracture in a Sliding Hip Screw Implant: A Unique Case Report |
| Q92095348 | Low acceptance of osteoanabolic therapy with parathyroid hormone in patients with fragility fracture of the pelvis in routine clinical practice: a retrospective observational cohort study |
| Q37025230 | Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures |
| Q26771715 | Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons |
| Q40908172 | Medication and bone metabolism: Clinical importance for fracture treatment |
| Q33716899 | Modeling and remodeling effects of intermittent administration of teriparatide (parathyroid hormone 1-34) on bone morphogenetic protein-induced bone in a rat spinal fusion model. |
| Q33790595 | Monitoring of Cellular Changes in the Bone Marrow following PTH(1-34) Treatment of OVX Rats Using a Portable Stray-Field NMR Scanner. |
| Q35909167 | More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery |
| Q35582118 | New technologies for the enhancement of skeletal repair: Challenges and opportunities. |
| Q33697036 | No effect of teriparatide on migration in total knee replacement |
| Q35947256 | Nonsurgical Corrective Union of Osteoporotic Vertebral Fracture with Once-Weekly Teriparatide |
| Q53826381 | Optimal administration frequency and dose of teriparatide for acceleration of biomechanical healing of long-bone fracture in a mouse model. |
| Q38272234 | Orthobiologics in the augmentation of osteoporotic fractures |
| Q34230286 | Orthopaedic surgeons' strategies in pharmacological treatment of fragility fractures |
| Q37250714 | Osseous Consolidation of an Aseptic Delayed Union of a Lower Leg Fracture after Parathyroid Hormone Therapy - A Case Report |
| Q38041419 | Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease |
| Q37084451 | PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patients |
| Q36084571 | PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis. |
| Q36756870 | PTH Induces Systemically Administered Mesenchymal Stem Cells to Migrate to and Regenerate Spine Injuries |
| Q36517935 | PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis |
| Q91843619 | PTH1-34 improves bone healing by promoting angiogenesis and facilitating MSCs migration and differentiation in a stabilized fracture mouse model |
| Q33965640 | Parameters for defining efficacy in fracture healing |
| Q37580945 | Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation |
| Q38550930 | Parathyroid hormone and its receptor gene polymorphisms: implications in osteoporosis and in fracture healing |
| Q27024513 | Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis |
| Q36464377 | Parathyroid hormone applications in the craniofacial skeleton |
| Q34690479 | Parathyroid hormone treatment increases fixation of orthopedic implants with gap healing: a biomechanical and histomorphometric canine study of porous coated titanium alloy implants in cancellous bone. |
| Q48702678 | Present at the beginning: a personal reminiscence on the history of teriparatide |
| Q51214369 | Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture. |
| Q30431697 | Prospects for osteoprogenitor stem cells in fracture repair and osteoporosis |
| Q38049741 | Protein and peptide-based therapeutics in periodontal regeneration |
| Q33988826 | Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism |
| Q37720477 | Radiographic features of teriparatide-induced healing of femoral fractures. |
| Q33711085 | Recommendations and considerations for the use of biologics in orthopedic surgery |
| Q36139114 | Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature |
| Q89749514 | Sacral Insufficiency Fractures: a Review of Risk Factors, Clinical Presentation, and Management |
| Q37866764 | Safety of long-term bisphosphonate therapy for the management of osteoporosis |
| Q42688632 | Short-term effects of teriparatide versus placebo on bone biomarkers, structure, and fracture healing in women with lower-extremity stress fractures: A pilot study |
| Q37043890 | Special Review: Accelerating fracture repair in humans: a reading of old experiments and recent clinical trials |
| Q35698772 | Subchondral insufficiency fracture of the knee: a non-traumatic injury with prolonged recovery time |
| Q37182730 | Successful treatment of nonunion with teriparatide after failed ankle arthrodesis for Charcot arthropathy |
| Q37109433 | Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. |
| Q35842659 | Systemic application of teriparatide for steroid induced osteonecrosis in a rat model |
| Q36189014 | Systemic intermittent parathyroid hormone treatment improves osseointegration of press-fit inserted implants in cancellous bone |
| Q43231238 | Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats |
| Q89935666 | Tarsal navicular stress fractures |
| Q50167168 | Teriparatide (human PTH1-34) compensates for impaired fracture healing in COX-2 deficient mice. |
| Q35967736 | Teriparatide - Indications beyond osteoporosis |
| Q91708726 | Teriparatide Associated with Fewer Refractures and Higher Body Heights of Cemented Vertebrae after Vertebroplasty: A Matched Cohort Study |
| Q36993481 | Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures |
| Q35165694 | Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials |
| Q33763443 | Teriparatide Treatment Improved Loosening of Cementless Total Knee Arthroplasty: A Case Report |
| Q36384656 | Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model |
| Q37590981 | Teriparatide anabolic therapy as potential treatment of type II dens non-union fractures |
| Q47136107 | Teriparatide and osseous regeneration in the oral cavity |
| Q37296379 | Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use. |
| Q33954158 | Teriparatide improves early callus formation in distal radial fractures |
| Q36116568 | Teriparatide in Fracture Non-Unions |
| Q44543490 | Teriparatide in the treatment of non-unions: scientific and clinical evidences |
| Q34544242 | Teriparatide therapy enhances devitalized femoral allograft osseointegration and biomechanics in a murine model |
| Q85216253 | Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases |
| Q90604024 | Testing a novel nanofibre scaffold for utility in bone tissue regeneration |
| Q51426697 | The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years. |
| Q57168746 | The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease |
| Q27010303 | The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials |
| Q90207923 | The Glycogen Synthase Kinase-3β Inhibitor LSN 2105786 Promotes Zebrafish Fin Regeneration |
| Q89896441 | The Treatment of Acute Diaphyseal Long-bones Fractures with Orthobiologics and Pharmacological Interventions for Bone Healing Enhancement: A Systematic Review of Clinical Evidence |
| Q87192653 | The administration of intermittent parathyroid hormone affects functional recovery from pertrochanteric fractured neck of femur: a protocol for a prospective mixed method pilot study with randomisation of treatment allocation and blinded assessment |
| Q37014846 | The administration of intermittent parathyroid hormone affects functional recovery from trochanteric fractured neck of femur: a randomised prospective mixed method pilot study |
| Q89560528 | The biology and treatment of acute long-bones diaphyseal fractures: Overview of the current options for bone healing enhancement |
| Q64107631 | The effectiveness and safety of parathyroid hormone in fracture healing: A meta-analysis |
| Q84890674 | The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats |
| Q92802336 | The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - In comparison with weekly teriparatide with bisphosphonate |
| Q40881729 | The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study |
| Q90184131 | The influence of parathyroid hormone 1-34 on the osteogenic characteristics of adipose- and bone-marrow-derived mesenchymal stem cells from juvenile and ovarectomized rats |
| Q28079160 | The role of peptides in bone healing and regeneration: a systematic review |
| Q36666097 | The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone |
| Q89184340 | Therapy of aseptic nonunions with parathyroid hormone |
| Q47099477 | Triweekly administration of parathyroid hormone (1-34) accelerates bone healing in a rat refractory fracture model. |
| Q30401258 | Updates in biological therapies for knee injuries: bone. |
| Q26801872 | Use of Teriparatide to improve fracture healing: What is the evidence? |
| Q38696905 | Use of teriparatide in osteoporotic fracture patients |
| Q39455766 | Use of teriparatide off-label: our experience and review of literature |
| Q34627029 | Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures |
| Q35605991 | Wnt signaling and orthopedics, an overview |
| Q88040650 | [Clinical results following conservative and surgical treatment of osteoporotic distal radius fractures in the elderly : Overview of best available evidence] |
| Q86441542 | [Insufficiency fractures of the pelvic ring] |
| Q85645564 | [Use of osteoanabolics in fracture nonunion] |
Search more.